Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;204(6 Suppl 1):S89-93.
doi: 10.1016/j.ajog.2011.03.005. Epub 2011 Mar 9.

Pharmacokinetics of oseltamivir according to trimester of pregnancy

Laura G Greer  1 , Richard D Leff, Vanessa Laibl Rogers, Scott W Roberts, George H McCracken Jr, George D Wendel Jr, Jeanne S Sheffield
Affiliations

Pharmacokinetics of oseltamivir according to trimester of pregnancy

Laura G Greer et al. Am J Obstet Gynecol. 2011 Jun.

Abstract

The purpose of this study was to determine pharmacokinetic parameters for oseltamivir in all trimesters of pregnancy. Thirty pregnant women, 10 per trimester, who were receiving oseltamivir phosphate (75 mg) were recruited to study first-dose pharmacokinetics. Plasma samples were obtained at 0, 0.5, 1, 2, 4, 8, and 12 hours after the first dose. Samples were analyzed for oseltamivir and oseltamivir carboxylate levels. With the use of a noncompartmental model, we estimated the area-under-the-curve, maximum concentration, time-to-maximum concentration, and half-life. There were no significant differences in the pharmacokinetics of oseltamivir by trimester, except for an increased half-life in the first trimester for oseltamivir phosphate and an increased maximum concentration in the third trimester for oseltamivir carboxylate. The levels of oseltamivir carboxylate that were observed were within the range that was needed to achieve inhibitory concentrations at 50% for pandemic H1N1. The pharmacokinetics of oseltamivir does not change significantly according to trimester of pregnancy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean concentrations of oseltamivir after first dose graphed by entire cohort and by trimester.
Figure 2
Figure 2
Mean concentrations of oseltamivir carboxylate after first dose graphed by entire cohort and by trimester.
See this image and copyright information in PMC

Comment in

References

    1. Jamison DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 Influenza virus infection during pregnancy in the USA. The Lancet. 2009;374:451–458. - PubMed
    1. Rasmussen SA, Jamieson DJ, MacFarlane K, Cragan JD, Williams J, Henderson Z. Pandemic Influenza and Pregnant Women: Summary of a Meeting of Experts. Am J Public Health. 2009;99 Supp 2:248–253. - PMC - PubMed
    1. Hewagama S, Walker SP, Stuart RL, et al. 2009 H1N1 Influenza A and Pregnancy Outcomes in Victoria, Australia. Clin Infect Dis. 2010;50:686–690. - PubMed
    1. Louie JK, Acosta M, Jamieson DJ, Honein M. Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in California. New Eng J Med. 2010;362(1):27–35. - PubMed
    1. Archer BN, Cohen C, Naidoo D, et al. Interim Report on Pandemic H1N1 influenza virus infections in South Africa, April to October 2009: Epidemiology and Factors Associated with Fatal Cases. Euro Surveill. 2009;14(42) pii=19369. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19369. - PubMed

Publication types

MeSH terms